Northg (301333.SZ) released its performance for the first three quarters, with net profit attributable to the parent company of 75.1803 million yuan, a year-on-year decrease of 21.33%.

Zhitong Finance APP News, R&G PharmaStudies (301333.SZ) released its 2026 third-quarter report. In the first three quarters, the company achieved operating revenue of 714 million yuan, a year-on-year increase of 17.52%. Net profit attributable to shareholders of the listed company was 75.1803 million yuan, a year-on-year decrease of 21.33%. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 66.0828 million yuan, a year-on-year decrease of 18.75%.